Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790974467> ?p ?o ?g. }
- W2790974467 endingPage "201" @default.
- W2790974467 startingPage "194" @default.
- W2790974467 abstract "Individuals with phenylketonuria (PKU) have a risk of cognitive impairment and inflammation. Many follow a low-phenylalanine (low-Phe) diet devoid of animal protein in combination with medical foods (MFs). To assess lipid metabolism in participants with PKU consuming amino acid MFs (AA-MFs) or glycomacropeptide MFs (GMP-MFs), we conducted fatty acid and metabolomics analyses. We used subsets of fasting plasma and urine samples from our randomized crossover trial in which participants with early-treated classical and variant (milder) PKU consumed a low-Phe diet combined with AA-MFs or GMP-MFs for 3 wk each. Fatty acid profiles of red blood cell (RBC) membranes were determined for 25 adults (aged 18–49 y) with PKU and 143 control participants. Metabolomics analyses of plasma and urine samples were conducted by Metabolon for 9–10 adolescent and adult participants with PKU and for 15 control participants. RBC fatty acid profiles were not significantly different with AA-MFs or GMP-MFs. PKU participants showed higher total n–6:n–3 (ω-6:ω-3) fatty acids (mean ± SD percentages of total fatty acids: AA-MF = 5.45% ± 1.07%; controls = 4.33%; P < 0.001) and lower docosahexaenoic acid (DHA; AA-MF = 3.21% ± 0.98%; controls = 3.70% ± 1.01%; P = 0.02) and eicosapentaenoic acid (AA-MF = 0.33% ± 0.12%; controls = 0.60% ± 0.43%; P < 0.001) in RBCs than did control participants. Despite higher carnitine intake from AA-MFs than GMP-MFs (mean ± SE intake: AA-MFs = 58.6 ± 5.3 mg/d; GMP-MFs = 0.3 ± 0.01 mg/d; P < 0.001), plasma concentrations of carnitine were similar and not different from those in the control group (AA-MF compared with GMP-MF, P = 0.73). AA-MFs resulted in higher urinary excretion of trimethylamine N-oxide (TMAO), which is synthesized by bacteria from carnitine, compared with GMP-MFs (mean ± SE scaled intensity—TMAO: AA-MFs = 1.2 ± 0.1, GMP-MFs = 0.9 ± 0.1; P = 0.005). Plasma deoxycarnitine was lower in PKU participants than in control participants, suggesting reduced carnitine biosynthesis in PKU (AA-MF = 0.9 ± 0.1; GMP-MF = 1.0 ± 0.1; controls = 1.3 ± 0.1; AA-MF compared with controls, P = 0.01; GMP-MF compared with controls, P = 0.04). Supplementation with DHA is needed in PKU. Carnitine supplementation of AA-MFs shows reduced bioavailability due, in part, to bacterial degradation to TMAO, whereas the bioavailability of carnitine is greater with prebiotic GMP-MFs. This trial was registered at www.clinicaltrials.gov as NCT01428258." @default.
- W2790974467 created "2018-03-29" @default.
- W2790974467 creator A5011509669 @default.
- W2790974467 creator A5017457305 @default.
- W2790974467 creator A5024470030 @default.
- W2790974467 creator A5043640133 @default.
- W2790974467 creator A5044005348 @default.
- W2790974467 creator A5078185313 @default.
- W2790974467 creator A5088808481 @default.
- W2790974467 date "2018-02-01" @default.
- W2790974467 modified "2023-10-14" @default.
- W2790974467 title "Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria" @default.
- W2790974467 cites W1604119928 @default.
- W2790974467 cites W1617526274 @default.
- W2790974467 cites W1904563748 @default.
- W2790974467 cites W1980692505 @default.
- W2790974467 cites W1984058072 @default.
- W2790974467 cites W1990591430 @default.
- W2790974467 cites W1993638259 @default.
- W2790974467 cites W2039518501 @default.
- W2790974467 cites W2050682021 @default.
- W2790974467 cites W2058919473 @default.
- W2790974467 cites W2062636802 @default.
- W2790974467 cites W2067669340 @default.
- W2790974467 cites W2072348905 @default.
- W2790974467 cites W2076021849 @default.
- W2790974467 cites W2078599166 @default.
- W2790974467 cites W2083190167 @default.
- W2790974467 cites W2086480881 @default.
- W2790974467 cites W2086792571 @default.
- W2790974467 cites W2110312890 @default.
- W2790974467 cites W2113622084 @default.
- W2790974467 cites W212643890 @default.
- W2790974467 cites W2132860088 @default.
- W2790974467 cites W2135073823 @default.
- W2790974467 cites W2136514772 @default.
- W2790974467 cites W2158479843 @default.
- W2790974467 cites W2164707581 @default.
- W2790974467 cites W2166129869 @default.
- W2790974467 cites W2174359622 @default.
- W2790974467 cites W2289014200 @default.
- W2790974467 cites W2300045235 @default.
- W2790974467 cites W2321624725 @default.
- W2790974467 cites W2341498653 @default.
- W2790974467 cites W2460747436 @default.
- W2790974467 cites W2464635447 @default.
- W2790974467 cites W2514877907 @default.
- W2790974467 cites W2587402341 @default.
- W2790974467 cites W2601583588 @default.
- W2790974467 cites W2605318983 @default.
- W2790974467 cites W2611505836 @default.
- W2790974467 cites W2621974975 @default.
- W2790974467 cites W2777898769 @default.
- W2790974467 cites W293005694 @default.
- W2790974467 cites W4248680598 @default.
- W2790974467 cites W4249433407 @default.
- W2790974467 doi "https://doi.org/10.1093/jn/nxx039" @default.
- W2790974467 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6251508" @default.
- W2790974467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29490096" @default.
- W2790974467 hasPublicationYear "2018" @default.
- W2790974467 type Work @default.
- W2790974467 sameAs 2790974467 @default.
- W2790974467 citedByCount "22" @default.
- W2790974467 countsByYear W27909744672018 @default.
- W2790974467 countsByYear W27909744672019 @default.
- W2790974467 countsByYear W27909744672020 @default.
- W2790974467 countsByYear W27909744672021 @default.
- W2790974467 countsByYear W27909744672022 @default.
- W2790974467 countsByYear W27909744672023 @default.
- W2790974467 crossrefType "journal-article" @default.
- W2790974467 hasAuthorship W2790974467A5011509669 @default.
- W2790974467 hasAuthorship W2790974467A5017457305 @default.
- W2790974467 hasAuthorship W2790974467A5024470030 @default.
- W2790974467 hasAuthorship W2790974467A5043640133 @default.
- W2790974467 hasAuthorship W2790974467A5044005348 @default.
- W2790974467 hasAuthorship W2790974467A5078185313 @default.
- W2790974467 hasAuthorship W2790974467A5088808481 @default.
- W2790974467 hasBestOaLocation W27909744671 @default.
- W2790974467 hasConcept C126322002 @default.
- W2790974467 hasConcept C134018914 @default.
- W2790974467 hasConcept C181199279 @default.
- W2790974467 hasConcept C185592680 @default.
- W2790974467 hasConcept C19038510 @default.
- W2790974467 hasConcept C2776091944 @default.
- W2790974467 hasConcept C2776991927 @default.
- W2790974467 hasConcept C2777171753 @default.
- W2790974467 hasConcept C2777431362 @default.
- W2790974467 hasConcept C2778078955 @default.
- W2790974467 hasConcept C2778435403 @default.
- W2790974467 hasConcept C2780026642 @default.
- W2790974467 hasConcept C515207424 @default.
- W2790974467 hasConcept C543025807 @default.
- W2790974467 hasConcept C55493867 @default.
- W2790974467 hasConcept C62231903 @default.
- W2790974467 hasConcept C71924100 @default.
- W2790974467 hasConceptScore W2790974467C126322002 @default.
- W2790974467 hasConceptScore W2790974467C134018914 @default.
- W2790974467 hasConceptScore W2790974467C181199279 @default.